10-Q: MannKind Q3 2025: Revenue Growth, Strategic Acquisition, Thirona Impairment

MannKind Corporation reports increased total revenues for Q3 and 9M 2025, driven by product sales, collaborations, and royalties, alongside the strategic acquisition of scPharmaceuticals Inc. and an impairment loss on its Thirona investment.

Summary

• Total revenues for the three months ended September 30, 2025, increased by 17% to $82.1 million, up from $70.1 million in the prior year.
• Total revenues for the nine months ended September 30, 2025, increased by 14% to $237.0 million, up from $208.7 million in the prior year.
• Net income for Q3 2025 was $8.0 million, a decrease from $11.6 million in Q3 2024, primarily due to a $6.4 million impairment loss on the Thirona investment.
• Net income for the nine months ended September 30, 2025, increased to $21.8 million from $20.2 million in the prior year.
• Commercial product sales increased by 13% to $22.3 million in Q3 2025 and by 8% to $63.7 million in 9M 2025.
• Afrezza net revenue increased by 23% in Q3 2025 and 13% in 9M 2025, driven by increased price and demand, and lower rebates.
• V-Go net revenue decreased by 19% in Q3 2025 and 11% in 9M 2025 due to lower demand, partially offset by increased price and improved gross-to-net percentage.
• Royalties from United Therapeutics' Tyvaso DPI sales increased by 23% in Q3 2025 to $33.3 million and by 26% in 9M 2025 to $94.6 million.
• The company completed the acquisition of scPharmaceuticals Inc. on October 7, 2025, for total consideration of up to $363.5 million, adding FUROSCIX to its product portfolio.
• A $6.4 million impairment loss was recognized in Q3 2025 for the investment in Thirona Bio, Inc., following its cessation of operations.
• Cash and cash equivalents significantly increased to $127.4 million as of September 30, 2025, from $46.3 million at December 31, 2024.
• Net cash provided by operating activities for 9M 2025 was $26.2 million, up from $19.9 million in 9M 2024.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and successfully executed a strategic acquisition, significantly expanding its product portfolio and securing substantial financing. While there was a notable impairment loss on an investment and some product sales declines, the overall financial health and strategic positioning appear improved, with a robust pipeline and increased liquidity. The increased R&D and SG&A expenses are largely tied to growth initiatives and acquisitions, which are positive long-term indicators despite short-term impact on net income.

Positives

• Strong revenue growth across all categories for both the three-month and nine-month periods, with total revenues increasing by 17% and 14% respectively.
• Afrezza net revenue increased significantly by 23% in Q3 2025 and 13% in 9M 2025, driven by increased price and higher demand, coupled with a decrease in rebates.
• Royalties from United Therapeutics' Tyvaso DPI sales showed substantial growth, increasing by 23% in Q3 2025 and 26% in 9M 2025, reflecting strong market performance of the partnered product.
• Successfully completed the strategic acquisition of scPharmaceuticals Inc. on October 7, 2025, expanding the product portfolio with FUROSCIX for chronic heart failure and kidney disease.
• Secured a new $500 million Blackstone Credit Facility, with an initial $75 million term loan funded and an additional $250 million drawn post-quarter for the scPharma acquisition, bolstering liquidity.
• Improved liquidity position with cash and cash equivalents increasing to $127.4 million as of September 30, 2025, from $46.3 million at December 31, 2024.
• Reduced interest expense on existing debt due to principal reductions from the senior convertible notes exchange and the repayment of MidCap and Mann Group notes in 2024.
• Progress in pipeline development with inhaled clofazimine (MNKD-101) in global Phase 3 and nintedanib (MNKD-201) initiating global Phase 2 trials.
• Reported an income tax benefit of $0.2 million for Q3 2025, compared to an expense of $1.3 million in Q3 2024.

Negatives

• Net income for Q3 2025 decreased to $8.0 million from $11.6 million in Q3 2024, primarily due to a $6.4 million impairment loss on the Thirona investment.
• V-Go gross and net revenues decreased significantly by 31% and 19% respectively in Q3 2025, and 30% and 11% respectively in 9M 2025, primarily due to lower demand.
• Increased inventory write-offs of $3.3 million in Q3 2025 and $8.3 million in 9M 2025, compared to $0.3 million and $1.9 million in the respective prior year periods.
• A significant loss on foreign currency transaction of $7.8 million for 9M 2025, a substantial increase from $0.5 million in 9M 2024.
• Selling, general and administrative expenses increased by $5.2 million (22%) in Q3 2025 and $15.4 million (22%) in 9M 2025, partly due to incremental costs associated with the scPharma acquisition.
• The investment in Thirona Bio, Inc. was fully impaired for $6.6 million in Q3 2025, including a $1.3 million write-off of previously recorded unrealized gains, following the cessation of its operations.
• The company did not realize a gain on bargain purchase in 2025, unlike the $5.3 million gain in 2024 from the Pulmatrix transaction.

Risks

• The commercial success of products like Afrezza, FUROSCIX, and Tyvaso DPI may be limited, impacting revenue generation.
• Manufacturing risks at the Danbury facility and with contract manufacturers in China (V-Go) and third parties (FUROSCIX) could affect production, cost, and quality.
• Reliance on limited and single-source suppliers for raw materials and components, with potential for supply chain disruptions and increased costs due to tariffs.
• International trade policies, including U.S.-China trade relations and tariffs, may adversely affect business and supply chain.
• Uncertainty regarding third-party payer coverage and adequate reimbursement for approved products could limit prescriptions and sales.
• The company may need to raise additional capital to fund operations, potentially leading to dilution or restrictive debt covenants.
• Risk of data or information technology system compromises, leading to regulatory actions, litigation, fines, and business disruptions.
• Operating results are expected to fluctuate, making future performance difficult to predict.
• Potential for future losses and insufficient cash flow from operations, impacting working capital and ability to service debt.
• The high rate of failure inherent in the R&D process for new drugs means there is no guarantee of successful commercialization for product candidates.
• Failure to achieve projected development goals in expected timeframes could harm business and stock price.
• Long-term safety and efficacy of approved products may differ from clinical studies, potentially leading to negative sales impact, reputational harm, or regulatory actions.
• Rapid technological change could render existing products or product candidates obsolete.
• The Blackstone Credit Facility contains restrictive covenants that may materially limit operating flexibility, and a default could adversely affect the financial position.
• Potential for product liability claims, with insurance coverage possibly being inadequate.
• Loss of key employees could materially harm operations and strategy.
• Ineffective internal controls over financial reporting could adversely affect business and stock price.
• Changes in tax laws or regulations, such as the OBBBA and IRA, or limitations on net operating loss carryforwards, could adversely affect financial performance.
• Compliance with environmental laws and regulations, including potential liabilities from past site operations, can be expensive.
• Cash balances exceeding federally insured limits at financial institutions pose a risk of loss in case of bank failures.
• The company's portfolio of investment securities may require registration with the SEC as an investment company under the Investment Company Act of 1940.
• Unstable market, economic, and geopolitical conditions, including international conflicts, could disrupt global trade, supply chains, and financial markets.

Future Outlook

The company expects continued patient enrollment in its global Phase 3 ICoN-1 clinical study for MNKD-101 into 2026 and anticipates initiating a global Phase 2 trial for MNKD-201 in early 2026. It also expects to ship Afrezza product to Cipla in India in the fourth quarter of 2025. The company believes its current resources, including cash, investments, product sales, royalties, and the Blackstone Credit Facility, will be sufficient to fund operations for at least the next 12 months.

Management Comments

• Our future success is dependent on our, and our current and future collaboration partners, ability to effectively commercialize approved products.
• Our future success is also dependent on our pipeline of new products.
• There is a high rate of failure inherent in the R&D process for new drugs. As a result, there is a high risk that the funds we invest in research programs will not generate sufficient financial returns.
• Products may appear promising in development but fail to reach market within the expected or optimal timeframe, or at all.
• We are actively monitoring this situation and exploring strategies to mitigate the risks [related to changes in tariff policy].
• We believe our resources will be sufficient to fund our operations for at least the next 12 months from the date of issuance of our condensed consolidated financial statements.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, significant regulatory hurdles, and intense competition. MannKind's strategic acquisition of scPharmaceuticals Inc. and its product FUROSCIX positions it to expand into the cardiovascular and renal care markets, diversifying beyond its existing diabetes and orphan lung disease focus. The continued growth in Tyvaso DPI royalties reflects a successful partnership in the orphan lung disease space, while the challenges with V-Go highlight the competitive pressures in the diabetes device market. The company's pipeline development in inhaled clofazimine and nintedanib indicates a commitment to addressing unmet medical needs in orphan lung diseases, a high-risk, high-reward segment. The industry also faces evolving challenges from healthcare legislation, drug pricing scrutiny, and global supply chain disruptions.

Comparison to Industry Standards

• The acquisition of scPharmaceuticals Inc. for up to $363.5 million, adding FUROSCIX, is a strategic move to diversify and expand market presence, comparable to other mid-sized biopharma companies seeking growth through M&A.
• The 10% royalty rate on Tyvaso DPI net sales, with 9% retained by the company, is a competitive rate for a licensed product, reflecting the value of the Technosphere platform.
• The company's gross margin for commercial product sales of 80% in Q3 2025 is generally strong for a pharmaceutical manufacturer, indicating efficient production or favorable pricing for its proprietary products like Afrezza.
• The high rate of R&D failure and the need for substantial capital are standard challenges in the biopharmaceutical industry, where only a small percentage of drug candidates successfully reach commercialization.
• The company's liquidity covenant of $40 million under the Blackstone Credit Facility is a common financial safeguard in debt agreements, reflecting standard lender requirements for maintaining financial stability.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to legal proceedings and claims that arise in the ordinary course of business, but does not anticipate a material adverse effect on its results of operations, financial position, or cash flows.

Related Party Transactions

• The Mann Group convertible note was discharged and terminated on April 2, 2024, with settlement involving common stock issuance and a cash payment.
• Rule 10b5-1 trading plans for stock disposition were adopted by CEO Michael Castagna, EVP/General Counsel David Thomson, and Director Steven B. Binder.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and stock-based compensation, but the scPharma acquisition and pipeline progress could offer long-term value.
• Employees are affected by management changes (Burkhard Blank's separation) and benefit from increased headcount and personnel-related costs in R&D and SG&A, as well as stock-based compensation plans.
• Customers benefit from the expansion of product offerings with FUROSCIX and continued availability of Afrezza and Tyvaso DPI, though third-party payer coverage and reimbursement policies remain a factor.
• Suppliers, particularly Amphastar for insulin, are subject to significant purchase commitments and capacity fees, with risks associated with single-source vendors and international trade policies.
• Creditors are impacted by the new Blackstone Credit Facility, which introduces significant debt and restrictive covenants, and the management of existing senior convertible notes.

Next Steps

• Continue patient enrollment in the global Phase 3 ICoN-1 clinical study for MNKD-101 into 2026.
• Initiate a global Phase 2 trial for MNKD-201 in early 2026.
• Ship Afrezza product to Cipla in India in the fourth quarter of 2025.
• Integrate scPharmaceuticals Inc. and its product FUROSCIX into operations.
• Provide required disclosures for the scPharma acquisition in future periods.
• Manage the Blackstone Credit Facility, including potential future draws and compliance with covenants.
• Monitor and mitigate risks related to international trade policies and supply chain.
• Evaluate the potential impact of new accounting standards (ASU No. 2023-09, ASU No. 2024-03, ASU No. 2025-05, ASU No. 2025-06).
• Continue to assess and manage the Insulin Supply Agreement with Amphastar, including purchase commitments and capacity fees.

Key Dates

Recommendation

MannKind demonstrates strong revenue growth across its core products and collaborations, notably with Tyvaso DPI royalties and Afrezza sales. The strategic acquisition of scPharmaceuticals Inc. and its product FUROSCIX offers significant diversification and growth potential in new therapeutic areas. The company has also secured substantial financing through the Blackstone Credit Facility, bolstering its liquidity. However, the quarter saw a significant impairment loss on the Thirona investment and continued declines in V-Go sales, indicating some operational challenges and investment risks. Increased operating expenses, while partly attributable to growth initiatives, also impacted short-term net income. Given the mix of strong growth in key areas, strategic expansion, and improved liquidity, balanced against the impairment, V-Go's performance, and the inherent risks of drug development and integration, a 'hold' recommendation is appropriate. Investors should monitor the successful integration of scPharma, the performance of FUROSCIX, and the progress of the pipeline candidates, as well as the company's ability to manage its debt obligations and operating expenses.

Keywords

biopharmaceutical, Afrezza, V-Go, Tyvaso DPI, FUROSCIX, diabetes, pulmonary arterial hypertension, PH-ILD, chronic heart failure, chronic kidney disease, inhaled insulin, treprostinil, furosemide, scPharmaceuticals, United Therapeutics, Blackstone Credit Facility, SEC filing, 10-Q, financial results, revenue, royalties, R&D, M&A, drug development, clinical trials, MNKD-101, MNKD-201